THE DEAL, AT A GLANCE
From the announcementAurenar
01What it doesAurenar's V-Link™ platform, which recently received breakthrough device designation from the FDA, delivers transauricular vagus nerve stimulation (taVNS) to modulate the…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by the Go Red for Women Venture Fund™, Solas BioVentures, BJC Health, Kaleida CapitalFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedAurenar raised $5.7M Seed, announced 2026-07-28From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersAurenar's $5.7M Seed financing is a smaller Healthcare & Life Sciences capital-flow signal, sitting at the 14th percentile of tracked sector rounds while the sector…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Aurenar · Financing Record
Explore source-linked visual explanations for Aurenar. Unsupported claims are withheld while source review continues.
Record 9140 · Recorded date: 2026-07-28
Explore company records →